Kevin Lalande, MBA, is a Co-Founder and Managing Director of Santé Ventures, a healthcare and life science venture capital firm founded in 2006 which currently manages over $500 million across three funds with 30+ portfolio company investments.
Over the last decade, the partners of Santé Ventures have helped create, build, and finance a valuable portfolio of innovative new venture-backed healthcare companies including LDR Medical (Nasdaq: LDRH, later acquired by ZimmerBiomet), Explorys (acquired by IBM Corp), AbVitro (acquired by Nasdaq: JUNO), Molecular Templates (Nasdaq:MTEM), Millipede Medical (acquired by Boston Scientific), TVA Medical (acquired by Becton Dickinson), and Claret Medical (acquired by Boston Scientific).
Kevin is also the Founder and Chief Investment Officer of Santé Capital, a systematic machine learning hedge fund that began trading capital in 2015 after three years of research and development. Kevin conceived the investment strategy, designed the original MindRank algorithms, and assembled a seasoned team to help drive this related line of business.
Before Santé Ventures and Santé Capital, Kevin spent seven years as an investment professional with Austin Ventures, a prominent venture capital firm with $4B under management. Prior to Austin Ventures, he was a management consultant with McKinsey & Company. Before McKinsey, he founded, built and sold three internet-based companies in the 1990’s. Kevin received a BS in Electrical & Computer Engineering with Honors in 1996 and an MBA with highest distinction from the Harvard Business School in 2001, where he was both a Baker Scholar and a Siebel Scholar.
Mr. Lalande joined the Lumos Pharma Board in 2014.
What is Kevin M. Lalande's net worth?
The estimated net worth of Kevin M. Lalande is at least $40,552.00 as of June 15th, 2022. Mr. Lalande owns 14,800 shares of Lumos Pharma stock worth more than $40,552 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Lalande may own. Learn More about Kevin M. Lalande's net worth.
How do I contact Kevin M. Lalande?
Has Kevin M. Lalande been buying or selling shares of Lumos Pharma?
Kevin M. Lalande has not been actively trading shares of Lumos Pharma in the last ninety days. Most recently, on Tuesday, September 7th, Kevin M. Lalande bought 10,000 shares of Lumos Pharma stock. The stock was acquired at an average cost of $11.11 per share, with a total value of $111,100.00. Learn More on Kevin M. Lalande's trading history.
Are insiders buying or selling shares of Lumos Pharma?
During the last twelve months, insiders at the sold shares 3 times. They sold a total of 6,059 shares worth more than $18,396.39. The most recent insider tranaction occured on April, 3rd when insider John C Mckew sold 2,214 shares worth more than $6,132.78. Insiders at Lumos Pharma own 25.4% of the company.
Learn More about insider trades at Lumos Pharma. Information on this page was last updated on 4/3/2024.
